News - CureVac
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
BioNTech wins round in CureVac mRNA patent dispute
2 days ago · CureVac – which is developing mRNA-based vaccines for COVID-19 and influenza with GSK – filed suit in the Düsseldorf Regional Court last year, claiming infringement of five patents. A judgment on...
CureVac Announces Positive Phase 2 Interim Data from COVID-19 …
Jan 5, 2024 · Results from the formal interim analysis showed that both vaccine candidates using CureVac's proprietary second-generation mRNA backbone produced meaningful immune responses and favorable...
GSK goes all-in on CureVac’s mRNA vaccines | pharmaphorum
1 day ago · GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and...
Why CureVac (CVAC) Stock Is Moving - Benzinga
2 days ago · Shares of CureVac fell by 12.3% Wednesday afternoon. The pullback may stem from profit-taking after Tuesday's strong gains driven by rising concerns over U.S. respiratory illnesses.
Why CureVac (CVAC) Stock Is Rising - Benzinga
4 days ago · In the case of CureVac, which is trading at $4.07 as of publishing time, $100 would buy you 24.57 shares of stock. If you're looking to bet against a company, the process is more complex.
CureVac’s CVGBM Cancer Vaccine Induces Promising Immune …
Sep 13, 2024 · In this highly aggressive and challenging cancer indication, preliminary immunogenicity results demonstrate that treatment with CVGBM-only following chemo-radiation therapy successfully induces cancer antigen-specific …
CureVac N.V. (CVAC) Latest Stock News & Headlines - Yahoo Finance
Nov 12, 2024 · Get the latest CureVac N.V. (CVAC) stock news and headlines to help you in your trading and investing decisions.
CureVac Announces Positive Data on Joint COVID-19 and Flu …
Jan 6, 2023 · Preliminary data from the modified, monovalent mRNA vaccine candidates CV0501 for COVID-19 and Flu-SV-mRNA for flu are being disclosed today, with final Phase 1 data to be published in due course.
CureVac gains $430M GSK vaccine contract, loses 30% of staff
Jul 3, 2024 · GSK is paying 400 million euros ($430 million) upfront for full rights to CureVac’s vaccines against influenza and COVID-19. The mRNA specialist shared news of the deal alongside a...
- Some results have been removed